Nichols & Pratt Advisers LLP Alnylam Pharmaceuticals, Inc. Transaction History
Nichols & Pratt Advisers LLP
- $1.4 Billion
- Q1 2025
A detailed history of Nichols & Pratt Advisers LLP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Nichols & Pratt Advisers LLP holds 1,043 shares of ALNY stock, worth $321,244. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,043
Previous 1,375
24.15%
Holding current value
$321,244
Previous $323,000
13.0%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
720Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.16 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.02 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.94 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.2 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.36 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $37.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...